Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

delta-Lactam derivative from thermophilic soil fungus exhibits in vitro anti-allergic activity

Full text
Author(s):
Show less -
Andrioli, W. J. [1] ; Santos, M. S. [2, 3] ; Silva, V. B. [1] ; Oliveira, R. B. [1] ; Chagas-Paula, D. A. [1] ; Jorge, J. A. [4] ; Furtado, N. A. J. C. [1] ; Pupo, M. T. [1] ; Silva, C. H. T. P. [1] ; Naal, R. M. Z. G. [2, 3] ; Bastos, J. K. [1]
Total Authors: 11
Affiliation:
[1] Univ Sao Paulo, Dept Ciencias Farmaceut, BR-14040903 Sao Paulo - Brazil
[2] Univ Sao Paulo, Dept Quim & Fis, Fac Ciencias Farmaceut Ribeirao Preto, BR-14040903 Sao Paulo - Brazil
[3] Univ Estadual Campinas, Inst Nacl Ciencia & Tecnol Bioanalit, Sao Paulo - Brazil
[4] Univ Sao Paulo, Dept Biol, Fac Filosofia Ciencias & Letras Ribeirao Preto, BR-14040903 Sao Paulo - Brazil
Total Affiliations: 4
Document type: Journal article
Source: NATURAL PRODUCT RESEARCH; v. 26, n. 23, p. 2168-2175, 2012.
Web of Science Citations: 1
Abstract

From cultures of thermophilic soil fungus Humicola grisea var thermoidea, a delta-lactam derivative (3-(2-(4-hydroxyphenyl)-2-oxoethyl)-5,6-dihydropyridin-2( 1H)-one) that displayed anti-allergic activity was isolated, which was predicted by in silico computational chemistry approaches. The in vitro anti-allergic activity was investigated by beta-hexosaminidase release assay in rat basophilic leukaemia RBL-2H3 cells. The delta-lactam derivative exhibited similar anti-allergic activity (IC50 = 18.7 +/- 6.7 mu M) in comparison with ketotifen fumarate (IC50 = 15.0 +/- 1.3 mu M) and stronger anti-allergic activity than azelastine (IC50 = 32.0 mu M). Also, the MTT cytotoxicity assay with RBL-2H3 cells showed that delta-lactam does not display cytotoxicity at concentrations lower than 50 mu M. This study suggests that the delta-lactam derivative has the potential to be used as a lead compound in the development of anti-allergic drugs for clinical use in humans. (AU)

FAPESP's process: 04/07935-6 - Bioprospection in fungi: the search of lead compounds for drug design and enzymes for pharmaceutical and industrial applications
Grantee:Jairo Kenupp Bastos
Support Opportunities: BIOTA-FAPESP Program - Thematic Grants